Neurocutaneous syndrome
MONDO:0042983A group of disorders characterized by ectodermal-based malformations and neoplastic growths in the skin, nervous system, and other organs.
Also known as: neurocutaneous syndrome, Phacomatoses, Phacomatosis, Phakomatoses, neurocutaneous disorder, neurocutaneous disorders, neuroectodermal dysplasia, neuroectodermal dysplasia syndrome
151 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Antioxidant drug shows promise for kids with NF1
Disease control CompletedThis study tested whether N-acetylcysteine (NAC), an antioxidant drug, can improve motor skills and learning in children with neurofibromatosis type 1 (NF1). Twenty-five children aged 8 to 16 took NAC or a placebo for 8 weeks. The goal was to see if NAC is safe and helps with mov…
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo shows promise for rare nerve tumors
Disease control CompletedThis phase 2 trial tested two drugs, selumetinib and sirolimus, in 21 people with advanced malignant peripheral nerve sheath tumors (MPNST), a rare cancer often linked to neurofibromatosis type 1. The goal was to see if the combination could shrink or stabilize tumors. The study …
Phase: PHASE2 • Sponsor: Sarcoma Alliance for Research through Collaboration • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could a cancer drug shrink NF2 tumors?
Disease control CompletedThis phase 2 trial tested the drug crizotinib in 12 people with neurofibromatosis type 2 (NF2) who had growing tumors in the ear area called vestibular schwannomas. Participants took crizotinib pills daily for up to 12 months. The main goal was to see if the drug could shrink the…
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New gel could shrink neurofibroma tumors without surgery
Disease control CompletedThis phase 2 trial tested a gel called NFX-179 on skin tumors in 199 adults with neurofibromatosis type 1. Participants applied the gel daily for 26 weeks. The study measured safety and whether tumors shrank in size or height. Results suggest the gel may help reduce tumor volume,…
Phase: PHASE2 • Sponsor: NFlection Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New epilepsy drug shows promise in long-term safety trial
Disease control CompletedThis study tested the long-term safety of a drug called LP352 (bexicaserin) in 41 people aged 12 to 65 with severe epilepsy syndromes like Dravet or Lennox-Gastaut. Participants took the drug three times daily for up to 52 weeks. The main goal was to check for side effects, while…
Phase: PHASE2 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for kids with brain tumors: targeted pill shows promise
Disease control CompletedThis study tested a drug called MEK162 in 105 children with low-grade gliomas or other tumors that have a specific overactive growth signal. The goal was to find the best dose, check for side effects, and see if the drug could shrink tumors. Children took the drug by mouth twice …
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New Gadolinium-Free MRI dye shows promise for brain scans
Diagnosis CompletedThis study tested a new MRI contrast agent called RVP-001, made with manganese instead of gadolinium, in 18 adults with known brain lesions (like tumors or multiple sclerosis). The goal was to see if it is safe and can detect lesions as well as current gadolinium-based dyes. Each…
Phase: PHASE2 • Sponsor: Reveal Pharmaceuticals Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 08:06 UTC
-
Teens with NF try video coaching to boost mood and health
Symptom relief CompletedThis study tested two 8-week stress management programs delivered via secure video calls for 196 adolescents aged 12–17 with neurofibromatosis (NF1 or NF2). The goal was to see if these programs could improve emotional, social, and physical quality of life. Both programs taught c…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Epidiolex shows promise for easing seizures and behavior issues in TSC
Symptom relief CompletedThis study looked at whether adding Epidiolex (a CBD-based medicine) to usual treatment can improve seizures, behavior, sleep, and quality of life in people aged 1 to 65 with tuberous sclerosis complex (TSC). 79 participants took the drug and were monitored for changes in symptom…
Phase: PHASE4 • Sponsor: Jazz Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Could a common supplement help kids with NF1 learn and move better?
Symptom relief CompletedThis study tested whether N-acetylcysteine (NAC), an over-the-counter antioxidant, could improve learning and motor skills in children with neurofibromatosis type 1 (NF1). Five children aged 8 to 16 took NAC or a placebo to see if it helped with movement and attention problems. T…
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Remote therapy shows promise for TSC behavior issues in preschoolers
Symptom relief CompletedThis study looked at behavior problems in 101 children aged 3 to 6 with tuberous sclerosis complex (TSC). Families completed assessments online, and those with elevated behavior issues were offered a parent-training therapy (PCIT) over the internet. The goal was to help parents m…
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Video-Based stress program aims to ease life with neurofibromatosis
Symptom relief CompletedThis study tested two stress and symptom management programs for adults with neurofibromatosis (NF1, NF2, or schwannomatosis). The programs were delivered through live videoconferencing over 8 weekly sessions. Researchers measured changes in quality of life and emotional well-bei…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Chill out: skin cooling may ease pain of NF1 treatments
Symptom relief CompletedThis study tested whether cooling the skin before or during laser and injection treatments for neurofibromatosis type 1 (NF1) skin bumps can reduce pain. Thirteen adults with NF1 received four different treatments (two lasers and two injections) on both cooled and non-cooled skin…
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Scientists track skin tumors in NF1 to uncover clues for future therapies
Knowledge-focused CompletedThis study followed 17 adults with neurofibromatosis type 1 (NF1) over two years to learn how their skin tumors (dermal neurofibromas) grow and change. Researchers used special cameras and skin biopsies to measure tumor growth and look for genes that might influence it. The goal …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
New scan and genetic tests aim to catch cancer early in NF1 patients
Knowledge-focused CompletedThis study looked at people with neurofibromatosis type 1 (NF1) to better understand how harmless tumors (plexiform neurofibromas) turn into a rare cancer called MPNST. Ten participants had MRI, PET scans, and tumor biopsies. Researchers tested whether a special PET scan (FLT PET…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Gene hunt aims to unlock NF1's mysteries
Knowledge-focused CompletedThis study looks at people with neurofibromatosis type 1 (NF1) and their families to find out why some have more severe symptoms than others. Researchers will collect medical history, blood samples, and images to study genes and physical traits. The goal is to identify genes that…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Frozen tumors, clearer vision? scientists dig into 20 years of eye records
Knowledge-focused CompletedThis study looks back at 20 years of medical records from 25 people who had a freezing treatment (cryotherapy) for retinal hemangioblastoma, a rare eye tumor often linked to von Hippel-Lindau disease. Researchers want to see how well the treatment controlled the tumors and affect…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Walking analysis sheds light on rare genetic disorders
Knowledge-focused CompletedThis study looked at whether a special walking test (3D gait analysis) can help identify movement problems in people with rare genetic diseases like Tuberous Sclerosis and STXBP1. About 40 participants aged 6 and older who could walk without help took part. The goal was to see if…
Sponsor: Universiteit Antwerpen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
20-Year study tests precision medicine for rare Brain-Skin disorders
Knowledge-focused CompletedThis completed study looked at 1,200 people with neurocutaneous syndromes (NF1, TSC, SWS, VHL) in Western China. Researchers compared those who received genetic testing, targeted drugs, and coordinated specialist care against those who got standard care. The goal was to see if pr…
Sponsor: West China Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
French study tracks port wine stains in kids to uncover hidden risks
Knowledge-focused CompletedThis study followed 150 children aged 2 to 12 who have a port wine stain on a leg. Researchers tracked how the stain changes as the child grows, and whether it leads to problems like blood vessel issues or bone growth differences. The goal was to learn more about the condition an…
Phase: NA • Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Scientists hunt for genes behind NF1 skin tumors
Knowledge-focused CompletedThis completed study at Stanford University looked at the DNA of over 1,000 adults with Neurofibromatosis Type 1 (NF1) to find genetic differences that might explain why some people develop more skin neurofibromas than others. Participants provided blood or saliva samples for gen…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New drug interaction study aims to make radiprodil safer for future use
Knowledge-focused CompletedThis study tested how the experimental drug radiprodil interacts with five common medications (warfarin, midazolam, digoxin, rosuvastatin, and omeprazole) in 18 healthy adults. Participants took radiprodil alone and then with each of these drugs to measure changes in drug levels …
Phase: PHASE1 • Sponsor: GRIN Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Eye tests reveal clues about neurofibromatosis
Knowledge-focused CompletedThis completed study looked at how the pigment layer of the eye works in 30 people with neurofibromatosis type 1. Researchers used special eye tests to measure electrical signals from the pigment layer and compared them to images of the back of the eye. The goal was to confirm ea…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:46 UTC